Find all relevant presentations and publications for each of our programs. From review papers to preclinical posters and clinical data presentations at medical conferences.
Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1; initiation of clinical trials anticipated in late 2024/early 2025
Axiomer activity demonstrated across multiple preclinical in vitro
